LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Price, Forecast & Analysis
USA - NYSEARCA:LCTX - US53566P1093 - Common Stock
LCTX Key Statistics, Chart & Performance
The current stock price of LCTX is 1.96 USD. In the past month the price increased by 14.62%. In the past year, price increased by 112.17%.
LCTX Latest News, Press Relases and Analysis
LCTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.43 | 374.44B | ||
| AMGN | AMGEN INC | 13.59 | 159.52B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.54 | 109.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.27 | 68.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.12 | 56.90B | ||
| ARGX | ARGENX SE - ADR | 61.62 | 50.87B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.04 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.99B | ||
| BIIB | BIOGEN INC | 9.05 | 22.20B |
Related stock screener links
About LCTX
Company Profile
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 70 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Company Info
LINEAGE CELL THERAPEUTICS IN
2173 Salk Avenue, Suite 200
Carlsbad CALIFORNIA 92008 US
CEO: Brian M. Culley
Employees: 74
Phone: 15105213390
LINEAGE CELL THERAPEUTICS IN / LCTX FAQ
What does LCTX do?
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 70 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
What is the stock price of LINEAGE CELL THERAPEUTICS IN today?
The current stock price of LCTX is 1.96 USD. The price increased by 2.08% in the last trading session.
Does LCTX stock pay dividends?
LCTX does not pay a dividend.
How is the ChartMill rating for LINEAGE CELL THERAPEUTICS IN?
LCTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of LINEAGE CELL THERAPEUTICS IN (LCTX) based on its PE ratio?
LINEAGE CELL THERAPEUTICS IN (LCTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
Is LINEAGE CELL THERAPEUTICS IN (LCTX) expected to grow?
The Revenue of LINEAGE CELL THERAPEUTICS IN (LCTX) is expected to grow by 4.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the outstanding short interest for LINEAGE CELL THERAPEUTICS IN?
The outstanding short interest for LINEAGE CELL THERAPEUTICS IN (LCTX) is 14.71% of its float.
LCTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LCTX. When comparing the yearly performance of all stocks, LCTX is one of the better performing stocks in the market, outperforming 96.77% of all stocks.
LCTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LCTX. While LCTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
LCTX Financial Highlights
Over the last trailing twelve months LCTX reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 14.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.06% | ||
| ROE | -84.55% | ||
| Debt/Equity | 0 |
LCTX Forecast & Estimates
13 analysts have analysed LCTX and the average price target is 4.25 USD. This implies a price increase of 116.84% is expected in the next year compared to the current price of 1.96.
For the next year, analysts expect an EPS growth of -99.62% and a revenue growth 4.62% for LCTX